Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Arena and Eisai attend end-of-review meeting with FDA for lorcaserin

Dec. 27, 2010

Corcept presents phase III data for Corlux for Cushing's syndrome

Dec. 27, 2010

Amylin and Lilly submit NDA for Byetta as an add-on therapy to basal insulin

Dec. 24, 2010

Living Cell Technologies adds patients to Diabecell trial in New Zealand

Dec. 24, 2010

AstraZeneca and Abbott discontinue development of Certriad for mixed dyslipidemia

Dec. 24, 2010

Leo Pharma divulges new positive modulators of calcium-sensing receptor

Dec. 24, 2010

Amylin submits initial sections of rolling BLA for metreleptin

Dec. 23, 2010

Isis begins phase I ISIS-APOCIIIRx trial to treat hypertriglyceridemia

Dec. 23, 2010

Novo Nordisk and Emisphere to develop oral insulin for diabetes

Dec. 23, 2010

Preclinical data presented on Radius Health's SARM RAD-140

Dec. 23, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...